HOOKIPA Pharma Inc. (HOOK) intrinsic value & 10-year financials
HOOKIPA Pharma Inc. (HOOK) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 33.9% a year to $43.9M, with an average return on invested capital of 56.5%.
- Graham intrinsic value
- —
- Revenue (FY2024)
- $43.9M
- Revenue growth (9-yr CAGR)
- 33.9%
- ROIC (10-yr avg)
- 56.5%
- Free cash flow (FY2024)
- -$77.2M
HOOK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $43.9M | -$43.5M | -$3.47 | -$77.2M | -117.1% | 985.9% |
| FY2023 | $20.1M | -$81.6M | -$0.86 | -$61.7M | -485.3% | 721.7% |
| FY2022 | $14.2M | -$64.9M | -$0.99 | -$25.0M | -513.4% | -507.1% |
| FY2021 | $18.4M | -$75.7M | -$1.15 | -$78.6M | -442.7% | -283.2% |
| FY2020 | $19.6M | -$44.1M | -$0.84 | -$41.7M | -272.1% | -255.4% |
| FY2019 | $11.9M | -$43.0M | -$1.21 | -$43.7M | -427.8% | -288.5% |
| FY2018 | $7.6M | -$16.2M | — | -$17.1M | -277.6% | 41.1% |
| FY2017 | — | -$12.7M | — | -$13.2M | — | 37.7% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
HOOKIPA Pharma Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
HOOKIPA Pharma Inc. returns on capital have been average, hovering around 10.3% ROIC over the decade.
HOOKIPA Pharma Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, HOOKIPA Pharma Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-115.26 per share.